Prognostic significance of the inhibitory-to-stimulatory immune checkpoint ratio in patients with breast cancer
We found that IDO1/TMIGD2 ratio was an independent prognostic factor for BRCA. On one hand, dual targeting of IDO1 and TMIGD2 may be a more effective therapeutic strategy for patients with a high IDO1/TMIGD2 ratio. On the other hand, ISICPR was a promising indicator with high clinical values and worthy of further promotion in other cancers.
Authors
- Xiaowen Hao (ORCID: https://orcid.org/0000-0002-0175-1186)
- Yuan Zeng (ORCID: https://orcid.org/0000-0002-3270-2459)
- Dawei Hao (ORCID: https://orcid.org/0000-0001-8586-5721)
- Chengling Chen
- Changwen Li
- Xiang Hu (ORCID: https://orcid.org/0000-0002-3751-430X)
- Tao Chen (ORCID: https://orcid.org/0000-0002-8217-2775)
- Chuangang Tang (ORCID: https://orcid.org/0000-0003-2447-5097)
- Yongcheng Li (ORCID: https://orcid.org/0000-0002-8869-5040)
- Pei Wang (ORCID: https://orcid.org/0009-0007-3968-6918)
Institutions
- Xuzhou Medical College (CN)
- Xuzhou Central Hospital (CN)
- Qilu Hospital of Shandong University (CN)
- Southeast University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-02-21
- DOI
- https://doi.org/10.3389/fonc.2025.1524861
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00